-
EP3426256
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3426256
| EP3426256 - METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.10.2020 Database last updated on 03.06.2024 | |
| Former | Request for examination was made Status updated on 14.12.2018 | ||
| Former | The international publication has been made Status updated on 15.09.2017 | Most recent event Tooltip | 09.10.2020 | Application deemed to be withdrawn | published on 11.11.2020 [2020/46] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US | [2019/03] | Inventor(s) | 01 /
LAURING, Brett 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | 02 /
ENGEL, Samuel, S. 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | 03 /
TERRA, Steven, G. 235 E. 42nd Street New York, New York 10017 / US | 04 /
RUSNAK, James, M. 235 E. 42nd Street New York, New York 10017 / US | [2019/03] | Representative(s) | Hussain, Deeba Merck Sharp & Dohme (UK) Limited 120 Moorgate London EC2M 6UR / GB | [N/P] |
| Former [2019/03] | Hussain, Deeba Merck Sharp & Dohme Limited Hertford Road Hoddesdon Hertfordshire EN11 9BU / GB | Application number, filing date | 17763809.5 | 06.03.2017 | [2019/03] | WO2017US20849 | Priority number, date | US201662306907P | 11.03.2016 Original published format: US 201662306907 P | [2019/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017155841 | Date: | 14.09.2017 | Language: | EN | [2017/37] | Type: | A1 Application with search report | No.: | EP3426256 | Date: | 16.01.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.09.2017 takes the place of the publication of the European patent application. | [2019/03] | Search report(s) | International search report - published on: | US | 14.09.2017 | (Supplementary) European search report - dispatched on: | EP | 04.10.2019 | Classification | IPC: | A61K31/7048, A61K31/155, A61K31/4985, A61K31/5513, A61K31/381, A61P9/10, A61P9/04 | [2019/45] | CPC: |
A61K31/357 (EP,US);
A61K31/155 (EP,US);
A61K31/4985 (EP,US);
A61K31/7048 (EP,US);
A61P9/04 (EP,US);
A61P9/10 (EP,US)
| C-Set: |
A61K31/155, A61K2300/00 (US,EP);
A61K31/4985, A61K2300/00 (EP,US);
A61K31/7048, A61K2300/00 (US,EP)
|
| Former IPC [2019/03] | A61K31/5513, A61K31/381 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/03] | Title | German: | VERFAHREN ZUR BEHANDLUNG ODER VERRINGERUNG DES RISIKOS KARDIOVASKULÄRER EREIGNISSE UND VERWANDTER KRANKHEITEN MITHILFE VON SGLT-2-INHIBITOREN | [2019/03] | English: | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | [2019/03] | French: | PROCÉDÉ DE TRAITEMENT OU DE RÉDUCTION DU RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES ET DE MALADIES ASSOCIÉES AU MOYEN D'INHIBITEUR DE SGLT-2 | [2019/03] | Entry into regional phase | 11.10.2018 | National basic fee paid | 11.10.2018 | Search fee paid | 11.10.2018 | Designation fee(s) paid | 11.10.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 02.10.2018 | Amendment by applicant (claims and/or description) | 11.10.2018 | Examination requested [2019/03] | 03.06.2020 | Application deemed to be withdrawn, date of legal effect [2020/46] | 25.06.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/46] | Divisional application(s) | EP20177822.2 / EP3735975 | Fees paid | Renewal fee | 08.03.2019 | Renewal fee patent year 03 | 10.03.2020 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] - ZINMAN BERNARD ET AL, "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes", NEW ENGLAND JOURNAL OF MEDICINE,, (20151101), vol. 373, no. 22, doi:10.1056/NEJMOA1504720, pages 2117 - 2128, XP002769966 [I] 1-14 * Discussion; page 2123 * DOI: http://dx.doi.org/10.1056/NEJMoa1504720 | International search | [Y]US2013137646 (WIENRICH MARION [DE], et al) [Y] 1-33 * , para [0080], [0088], [0089], [0127], [0145], [0267], [0268] *; | [Y]US2014303097 (BROEDL ULI CHRISTIAN [DE], et al) [Y] 1-33 * , para [0054], [0248], [0296], [0312], [0313] *; | [Y]US2010056618 (MASCITTI VINCENT [US], et al) [Y] 1-33 * , para [0007], [0013], [0015] * |